02-Jun-2022 - Helmholtz-Zentrum für Infektionsforschung GmbH

A precision cut for the CRISPR-Cas genetic scissors

A new study indicates how deep learning can improve gene therapies and antiviral drugs

The nuclease Cas13b associated with CRISPR defense systems—also known as genetic scissors—has the potential to be used in the future in hereditary diseases to silence adverse genes. In the fight against infections, it is also being researched as an antiviral agent, as Cas13b can target the genome of viruses and render them harmless. Despite these promising features, researchers are looking for nuclease inhibitors that can control or stop such activities. The aim is to increase the safety and efficacy of future therapies and to help prevent off-target effects. An international team led by the Helmholtz Institute in Würzburg in cooperation with the University of Freiburg has now applied deep learning for the first time to find natural nuclease inhibitors. The study, published in the scientific journal "Molecular Cell", identified the first such inhibitor that blocks the activity of Cas13b.

Bacteria often contain CRISPR-Cas defense systems that protect against viral invaders called phages. In response, phages have evolved proteins that can shut down CRISPR. These are called anti-CRISPR proteins, or Acrs. Researchers believe that there are numerous Acrs that have not yet been discovered. One of those is Chase Beisel, head of the RNA Synthetic Biology Department at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a site of the Helmholtz Centre for Infection Research (HZI) in Braunschweig in cooperation with the Julius-Maximilians-Universität (JMU) Würzburg. "Acrs can be used to better control CRISPR technologies," Beisel says, while acknowledging, "Identifying them means finding a needle in a haystack, since they look nothing like each other." This, he says, has led scientific studies in the past to come up with new prediction tools. However, the success of these methods has been limited, says Beisel. He initiated the study published in the journal “Molecular Cell”.

First example of using deep learning for Acr discovery

Consequently, a team of researchers from the HIRI in Würzburg, together with scientists from the Signalling Research Centres at the University of Freiburg and the Information and Computer Science Department at King Fahd University in Saudi Arabia, has pioneered the use of artificial intelligence to identify new Acrs.

"Using complex computational learning in combination with a high-throughput screen, we have succeeded in discovering a new anti-CRISPR protein that inhibits the clinically interesting nuclease Cas13b," says Katharina Wandera. The PhD student in Chase Beisel's lab is working on the characterization of Acrs and is a first author of the current paper.

"The millions of predictions made by our algorithm open up completely new avenues for research," Rolf Backofen from the University of Freiburg is certain. His group developed the method, called DeepAcr, for the study.

The findings also suggest that DeepAcr can not only be used to discover new proteins that inhibit CRISPR-Cas systems lacking known Acrs. "The identified anti-CRISPR protein AcrVIB1 was not only unknown until now, it also seems to use a completely new mechanism of action," summarizes Omer Alkhnbashi, an assistant professor at King Fahd University who shares the first authorship with Wandera.

Characterizing this mechanism of action is one of the next steps that will now follow the scientific work.

Facts, background information, dossiers

  • hereditary diseases
  • deep learning
  • inhibitors

More about Helmholtz-Zentrum für Infektionsforschung

  • News

    Two bugs with one stone

    The development of new active substances against pathogenic bacteria, parasites, fungi and viruses is gaining importance, as established antiinfectives are becoming increasingly ineffective due to the development of resistance. At the Helmholtz Institute for Pharmaceutical Research Saarland ... more

    New “decision aid” for CRISPR immune responses

    Friend or foe? Immune systems constantly face this question. They must recognize and clear foreign invaders without eliciting autoimmunity. Prokaryotic CRISPR-Cas systems recognize invaders based on genetic sequence. But what happens if the host genome shares the same sequences? A research ... more

    A boost for CRISPR research

    For many diseases, the tools of medicine are reaching their limits. CRISPR technologies open new avenues for diagnostics and therapies, although the natural source of CRISPR remains largely untapped. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg ... more

  • q&more articles

    Antibiotic resistance

    Do you also find it tiresome and disagreeable when tasks long-since done and dusted suddenly resurface, appear never to have been finished in the first place and now need your urgent attention? In drug research, the topic of antibiotics is a shining – and simultaneously appalling – example ... more

  • Authors

    Prof. Dr. Mark Brönstrup

    studied Chemistry at Philipps University Marburg (Germany) and London’s Imperial College. He obtained his doctorate in organic chemistry in 1999 from TU Berlin. From 2000 to 2013, he worked at the pharmaceutical company Sanofi in Frankfurt, first as head of a mass spectrometry lab before mo ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by: